Effects of sacubitril-valsartan in the treatment of chronic heart failure patients with end-stage renal disease undergoing dialysis.

Xiaoyan LiuLidong HuangGary TseTong LiuJing-Jin Che

Published in: Clinical cardiology (2023)

Our study found that LCZ696 treatment was associated with a reduction in HF rehospitalization without significant effects on serum creatinine and serum potassium levels. LCZ696 is effective and safe in CHF patients with ESRD on dialysis.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
ejection fraction
heart failure
metabolic syndrome
combination therapy